ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

About ANI Pharmaceuticals

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANIP
  • CUSIP:
Key Metrics:
  • Previous Close: $67.66
  • 50 Day Moving Average: $64.783
  • 200 Day Moving Average: $53.300
  • 52-Week Range: $26.80 - $70.92
  • Trailing P/E Ratio: 77.961
  • Foreward P/E Ratio: 14.23
  • P/E Growth: 1.080
  • Market Cap: $763.90M
  • Outstanding Shares: 11,514,000
  • Beta: 2.84
  • Net Margins: 11.02%
  • Return on Equity: 20.12%
  • Return on Assets: 11.02%
  • Debt-to-Equity Ratio: 0.71%
  • Current Ratio: 3.23%
  • Quick Ratio: 2.21%
Additional Links:
Companies Related to ANI Pharmaceuticals:

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.67 (0.78% downside)

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateFirmActionRatingPrice TargetDetails
8/5/2016GuggenheimReiterated RatingBuy$65.00 -> $80.00View Rating Details
8/5/2016Oppenheimer Holdings Inc.Boost Price TargetOutperform$65.00 -> $71.00View Rating Details
7/19/2016Citigroup Inc.UpgradeOutperform$65.00View Rating Details
6/22/2016Raymond James Financial Inc.Initiated CoverageStrong-Buy$68.00View Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
11/4/2015Roth CapitalReiterated RatingBuy$60.00 -> $56.00View Rating Details
(Data available from 9/29/2014 forward)


Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.57$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.58$0.67$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.46$0.66$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214$0.01($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $4.12 EPS
Next Year EPS Consensus Estimate: $4.65 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.24$0.24$0.24
Q2 20161$0.78$0.78$0.78
Q3 20161$0.94$0.94$0.94
Q4 20161$1.06$1.06$1.06
(Data provided by Zacks Investment Research)


Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Ownership Percentage: 31.60%
Institutional Ownership Percentage: 48.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.00View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
DateHeadline logoANI Pharma Launches Erythromycin Ethylsuccinate For Oral Suspension, 200mg/5mL (NASDAQ:ANIP) - September 29 at 3:44 PM
News IconNotable movements of Stock: AgroFresh Solutions, Inc. (NASDAQ:AGFS) , ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Wall Street Times (press release) (NASDAQ:ANIP) - September 28 at 3:28 PM logoANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL - Yahoo Finance (NASDAQ:ANIP) - September 28 at 8:18 AM logoANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL - PR Newswire (press release) (NASDAQ:ANIP) - September 27 at 3:31 PM logo8:32 am ANI Pharma announced the immediate launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL as a treatment for various infections (NASDAQ:ANIP) - September 27 at 3:31 PM logoANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL (NASDAQ:ANIP) - September 27 at 3:31 PM logoShares Of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected To Hit $73 - Investor Newswire (NASDAQ:ANIP) - September 26 at 3:29 PM logoLigand Inks CNS License Agreement with Seelos Therapeutics - Nasdaq (NASDAQ:ANIP) - September 23 at 3:55 PM logoAstraZeneca Withdraws Cediranib Marketing Application in EU - Yahoo Finance (NASDAQ:ANIP) - September 22 at 3:28 PM logoDicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6% (NASDAQ:ANIP) - September 22 at 9:23 AM logoPuma (PBYI) Neratinib's NDA Accepted for Review, Stock Up (NASDAQ:ANIP) - September 21 at 4:25 PM logoRegenxbio (RGNX) Worth Watching: Stock Adds 5.3% in Session (NASDAQ:ANIP) - September 21 at 9:14 AM logoProQR Therapeutics (PRQR) Catches Eye: Stock Rises 8.2% (NASDAQ:ANIP) - September 21 at 9:14 AM
News IconShares Have Ticked Up Over the Last Five Trading Sessions: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Post News (NASDAQ:ANIP) - September 20 at 3:31 PM logoIdera Pharmaceuticals in Focus: Stock Adds 8.8% in Session (NASDAQ:ANIP) - September 20 at 9:26 AM logoCoLucid Pharmaceuticals (CLCD) in Focus: Stock Jumps 7.4% (NASDAQ:ANIP) - September 20 at 9:26 AM logoCara Therapeutics (CARA) Catches Eye: Stock Rises 5.7% (NASDAQ:ANIP) - September 20 at 9:26 AM logoHalozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9% (NASDAQ:ANIP) - September 19 at 8:15 AM
News IconStock Perspective: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Earnings in View - Frisco Fastball (NASDAQ:ANIP) - September 17 at 8:19 AM logoSarepta Shares Soar on News of Key Drug Critic FDA Exit - Nasdaq (NASDAQ:ANIP) - September 15 at 8:39 PM logoSanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised) (NASDAQ:ANIP) - September 15 at 3:30 PM
News IconAni Pharmaceuticals Incorporated (NASDAQ:ANIP) Shorts Decreased by 6.09% After Short Covering - Post News (NASDAQ:ANIP) - September 15 at 12:25 PM
News IconNew Market Research Report: Biovia - Pharmaceuticals & Healthcare - Deals and Alliances Profile (NASDAQ:ANIP) - September 14 at 8:46 PM logoANI Pharmaceuticals (ANIP) Sees Hammer Chart Pattern; Time to Buy? (NASDAQ:ANIP) - September 14 at 3:32 PM logoANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : September 14, 2016 (NASDAQ:ANIP) - September 14 at 3:32 PM logoSanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (NASDAQ:ANIP) - September 14 at 8:31 AM logo4 Biotech Stocks to Buy as Election Fever Rises (NASDAQ:ANIP) - September 13 at 3:29 PM
News IconConsensus Analyst Opinions for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , GTT Communications, Inc. (NYSE:GTT) - Wall Street Times (press release) (NASDAQ:ANIP) - September 12 at 8:18 AM logoEpizyme Non-Hodgkin Lymphoma Drug Clears Futility Hurdle (NASDAQ:ANIP) - September 8 at 11:03 AM logoAlnylam (ALNY) Reports Positive Phase I Data on ALN-AS1 (NASDAQ:ANIP) - September 8 at 11:03 AM logoExelixis Reports Interim Analysis of Liver Cancer Trial Data (NASDAQ:ANIP) - September 7 at 3:29 PM logoCoLucid Hits 52 Week High on Positive Data on Migraine Drug (NASDAQ:ANIP) - September 7 at 12:28 PM logoCompugen (CGEN) Looks Good: Stock Adds 5.1% in Session (NASDAQ:ANIP) - September 6 at 3:29 PM logoETF’s with exposure to ANI Pharmaceuticals, Inc. : September 6, 2016 (NASDAQ:ANIP) - September 6 at 3:29 PM logoAmgen Gets FDA Approval for Label Expansion of Blincyto (NASDAQ:ANIP) - September 2 at 8:09 AM logoWhat Makes Editas Medicine (EDIT) a Strong Sell? (NASDAQ:ANIP) - September 1 at 11:58 AM logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : August 31, 2016 (NASDAQ:ANIP) - September 1 at 11:58 AM logoARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib (NASDAQ:ANIP) - August 31 at 3:30 PM logoCoLucid Pharmaceuticals (CLCD) Jumps: Stock Rises 12.1% (NASDAQ:ANIP) - August 31 at 8:18 AM logoCTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up (NASDAQ:ANIP) - August 30 at 11:23 AM logoRoche Gets FDA Nod for Emergency Use of Zika Virus Test (NASDAQ:ANIP) - August 29 at 8:17 AM
News IconDisastrous, Negative Day (NASDAQ:ANIP) - August 25 at 8:18 AM logoWill ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Hit $73 Price Target? - Investor Newswire (NASDAQ:ANIP) - August 22 at 8:18 AM logoWhy ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? (NASDAQ:ANIP) - August 18 at 11:54 AM logoHow ANI Pharmaceuticals (ANIP) Stock Stands Out in a Strong Industry - Nasdaq (NASDAQ:ANIP) - August 17 at 3:33 PM logoHow ANI Pharmaceuticals (ANIP) Stock Stands Out in a Strong Industry (NASDAQ:ANIP) - August 17 at 11:43 AM logoANI PHARMACEUTICALS : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A) (NASDAQ:ANIP) - August 16 at 8:47 PM logoANI PHARMACEUTICALS INC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ANIP) - August 16 at 8:47 PM logoCan The Uptrend Continue for ANI Pharmaceuticals (ANIP)? (NASDAQ:ANIP) - August 16 at 12:07 PM logoMid Cap Unusual Volume: ANI Pharmaceuticals (NASDAQ:ANIP), Copa Holdings (NYSE:CPA), Summit State Bank ... - KC Register (NASDAQ:ANIP) - August 15 at 10:45 AM


ANI Pharmaceuticals (NASDAQ:ANIP) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff